Additionally, studies have identified apolipoprotein L3 (APOL3) as a key player in CRC, enhancing CD8+ T-cell antitumor activity by promoting ubiquitin-mediated degradation of lactate dehydrogenase A (LDHA), making it a potential biomarker for ferroptosis-based immunotherapy (69). Here, APOL3 is linked to colorectal carcinoma.